Hyperlipidaemia News

  • 27 November 2019
    Reports from the 11th Closed Expert Meeting of the PCSK9 Education and Research Forum Ruth Frikke-Schmidt  The post Emerging lipid science: ApoE and chronic disease appeared first on PCSK9 Forum.
  • 20 November 2019
    In patients with recent acute coronary syndrome (ACS) and dyslipidaemia despite intensive statin therapy, alirocumab decreased the risk of ischaemic stroke without increasing haemorrhagic stroke, irrespective of baseline LDL-C and history of cerebrovascular disease, over a median follow-up of 2.8 years. ODYSSEY OUTCOMES (NCT01663402) compared...
  • 20 November 2019
    In patients with recent ACS, alirocumab improves outcomes irrespective of age. Increasing treatment benefit but not harm with advancing age suggests that marked LDL-C lowering is an important secondary preventive intervention for older patients. Previously, the ODYSSEY OUTCOMES trial compared alirocumab with placebo, added to high-intensity or...
  • 20 November 2019
    LIB003, a novel recombinant fusion protein therapeutic agent consisting of a PCSK9-binding domain (adnectin) and human serum albumin, provides maximal stable mean reductions of LDL-C of nearly 60% from baseline in high-risk patients with hypercholesterolaemia and was well tolerated. Dr Evan Stein (LIB Therapeutics and Metabolic &...
  • 20 November 2019
    A Japanese research group showed that treatment with alirocumab reduces LDL-C, a highly atherogenic molecule (LOX-1) and N-terminal pro-brain natriuretic peptide (NT-pro BNP) in a small study of patients following acute myocardial infarction.1 The acute effects of PCSK9 inhibitors on MI patients has not previously been clear. These early findings...
  • 20 November 2019
    New patient-centred outcomes data from the ODYSSEY OUTCOMES trial* (NCT01663402) in patients with acute coronary syndrome (ACS) shows that alirocumab compared with placebo reduced total hospitalisations, increased days alive and out of hospital (DAOH) and increased the likelihood of survival without hospitalisation. Over a median 2.8 years of...
  • 20 November 2019
    Two new analyses from the FOURIER trial have provided further information on the impact of evolocumab on patients’ every day cognition and on cardiovascular outcomes following a recent myocardial infarction (MI). The FOURIER study randomized 27,564 pts with stable atherosclerotic cardiovascular disease (ASCVD) treated with statins to evolocumab vs...
  • 20 November 2019
    Results presented at AHA 2019 demonstrated that twice-yearly inclisiran reduced LDL-C by 50% in patients with heterozygous familial hypercholesterolaemia (HeFH). The ORION-9 study (NCT03397121) met all its primary and secondary efficacy endpoints and 50% LDL-C lowering was observed at day 510 (p<0.0001) with a 45% time-adjusted LDL-C lowering...
  • 20 November 2019
    In the ORION-10 trial (NCTNCT03399370) twice-yearly inclisiran safely reduced LDL-C in patients with atherosclerotic cardiovascular disease (ASCVD) with continued high LDL-C despite being on maximum tolerated statin dose. Full study results were presented during a late-breaking science session at the American Heart Association (AHA) Scientific...
  • 30 October 2019
    A one-year follow up of the ORION-1 study (Clinical Trial NCT02597127: https://clinicaltrials.gov/ct2/show/NCT02597127) suggests that inclisiran may offer a novel approach to LDL-C reduction with the convenience of less frequent dosing. The study involved prespecified analysis of the randomised, double-blind, placebo-controlled multicentre phase 2...
  • 30 October 2019
    Final data from the OSLER-1 (Open-Label Study of Long-term Evaluation against LDL-C) study has been published, highlighting the sustained LDL-C lowering efficacy, tolerance and safety of evolocumab in the longest duration study of a PCSK9 inhibitor reported to date. These data were first reported by Koren et al. at the AHA Scientific Sessions in...
  • 30 October 2019
    A pooled post-hoc analysis from ten phase 3 ODYSSEY trials shows that alirocumab gives consistent LDL-C reductions with similar safety findings across different BMI subgroups. The study was conducted as increased BMI contributes to cardiovascular risk and may influence the efficacy of therapeutic antibodies. Data were pooled from 4975 subjects in...
  • 30 October 2019
    The Medicine Company has reported positive top line results for the ORION-9 and ORION-10 phase 3 clinical studies of inclisiran in heterozygous familial hypercholesterolaemia patients and atherosclerotic cardiovascular disease patients (ASCVD). Detailed efficacy, tolerability and safety data from both studies will be presented at the AHA...
  • 25 October 2019
    Reports from the 11th Closed Expert Meeting of the PCSK9 Education and Research Forum Gabriel Steg & Gregory Schwartz  The post ODYSSEY OUTCOMES: Update appeared first on PCSK9 Forum.
  • 25 October 2019
    Reports from the 11th Closed Expert Meeting of the PCSK9 Education and Research Forum Robert Giugliano  The post New data from FOURIER and design of the VESALIUS-CV Trial appeared first on PCSK9 Forum.
  • 25 October 2019
    Reports from the 11th Closed Expert Meeting of the PCSK9 Education and Research Forum Professor Catherine Boileau  The post PCSK9 Genetics: New Insights appeared first on PCSK9 Forum.
  • 24 September 2019
    The post VIDEO: Prof PG Steg Targeting PCSK9 inhibition appeared first on PCSK9 Forum.
  • 24 September 2019
    The post VIDEO: Prof Greg Schwartz Candidates for PCSK9 inhibition appeared first on PCSK9 Forum.
  • 24 September 2019
    The post VIDEO: Prof Eric Bruckert EAS FHSC Registry appeared first on PCSK9 Forum.
  • 24 September 2019
    The post VIDEO: Prof Eric Bruckert LDL goals in FH appeared first on PCSK9 Forum.

Pages